British Columbia-based HYTN Innovations Inc (CNSX: HYTN) (OTCMKTS: HYTNF) (FRA: 85W0) says German authorities have deemed its cannabinoid products to be up to their standards. These recently imported goods will now be released into Germany’s market.
On Mar. 27, the company made the announcement and explained that it will be shipping more merchandise to the European country in the near future.
“The successful release of product into the German market is a significant commercial milestone,” said HYTN chief executive Elliot McKerr. “It validates that our GMP platform meets the stringent requirements of one of the world’s most tightly regulated medical cannabis markets.”
The company operates a GMP-certified facility and holds a comprehensive suite of Health Canada licenses, including for cannabis cultivation/processing/medical sales, psilocybin cultivation, and research.
HYTN collaborates with Canadian cannabis producers and international distributors/pharmaceutical partners to process flower into GMP-compliant finished goods. These include beverages, edibles, extracts and topicals.
What sets HYTN apart from others is its proprietary Elevation Technology. According to the company’s own studies, this nano-emulsification process delivers rapid, predictable, consistent effects with significantly higher bioavailability and absorption. This assertion lacks peer review.
Elevation tech powers the HYTN-branded lineup of cannabis-infused, sugar-free, calorie-free, gluten-free beverages and “Nano-Shots” plus all-natural edibles distributed through Canadian retailers. The HYTN Nano Shot is a citrus flavoured, high-potency (100 milligrams total) low-volume liquid THC product. Consumers use a dropper for precision dosing.
This German market entry, paired with an accepted reorder, represents a concrete commercial validation for HYTN after years of building GMP capabilities and securing supply partnerships.
Whether this momentum translates into broader market share and improved financial performance remains to be seen, but the recent developments underscore HYTN’s ambition to compete in both medical export and recreational channels.
For the three-month period ending Dec. 31, HYTN saw its revenue rise immensely. The company brought in C$1.46 million, representing a 644 per cent year-over-year increase. This surge was largely driven by GMP cannabis processing sales, meaning fees HYTN earns by manufacturing products for other companies using its licensed high-tech production facility.
However, the company still posted a net loss of C$288,000 and saw its cash drop sharply to C$57,000. With a growing deficit and a working capital shortfall of C$1.48 million, management has warned that the company needs external funding to continue operating.
“Management is aware of the company’s reliance on external funding through equity and debt financing, which leads to a material uncertainty which casts doubts on the company’s ability to continue as a going concern,” HYTN said in its latest financial filing.
Read more: Yukoners lead charge with national cannabis consumption as alcohol sales decline
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
